Effects Of Rosuvastatin Daily Or Every-Other-Day On Lipid Profile And Inflammatory Markers In Elderly Patients With Hyperlipidemia

ObjectiveTo investigate effects of rosuvastatin daily or every-other-day on blood lipid and inflammatory markers in elderly patients with hyperlipidemia.Methods From February 2017 to February 2018,a total of 312 elderly patients?age?75years old?with LDL-C?3.4mmol/L?130mg/ml?who had hypertension or at least one risk factor,and over cared at Tangshan Gongren Hospital Group were included in this study.The daily medication group?n=153?was initiated on 10mg rosuvastatin daily and every-other-day medication group?n=159?was given rosuvastatin 10 mg every other day,followed up for 1 year.The patients were instructed to maintain a good diet and lifestyle.Changes in LDL-C,TC,TG,HDL-C,Lp?a?,Apo A1,Apo B,hs-CRP,IL-6,Lp-PLA₂,Hcy,AST,ALT,CK,Cre,BUN and FBG were measured before treatment,12 weeks,and 1year after treatment.And recorded costs,adverse reactions,medication compliance and MACE in both groups.Results 1 After 12 weeks,the levels of LDL-C,TC,TG,Apo B,LP?a?and HDL-C in the daily and every-other-day medication groups were significantly changed compared with those before administration,and the levels on TC and LDL-C of daily medication group is lower than another group?P<0.05?.The levels of Apo A1 in the two groups were higher than those before treatment,but there was no significant difference?P>0.05?.At 1 year,the levels of LDL-C,Apo B and Lp?a?in the two groups were significantly lower than those at12 weeks?P<0.05?.The level of Apo A1 in the daily medication group was higher than that before treatment?P<0.05?.There was no significant change in the Apo A1 level in the every-other-day group?P>0.05?.At 1 year,there was no significant difference in blood lipid between the two groups?P>0.05?.At the end of the treatment,TC,TG,LDL-C,Apo B and LP?a?decreased by 32.00%,12.93%,45.77%,14.21%and 25.44%,respectively,and HDL-C and Apo A1 increased by 12.58%,and 16.72%.The changes in the daily medication group were 33.29%,16.21%,48.99%,16.46%,29.63%,11.79%and 27.36%,respectively,and there was no statistical difference?P>0.05?.The rate of reaching target goal of every-other-day medication group?74.07%?was lower than daily medication group?80.00%?,but the difference was not statistically significant?P>0.05?.2 After 12 weeks of statin treatment,the level of Lp-PL A₂,hs-CRP,IL-6 and Hcy in every-other-day medication group were?220.42±47.58?mg/L,?4.34±1.50?mg/L,?216.97±53.36?pg/ml,?15.38±2.50?umol/L.In daily medication group,Lp-PL A₂,hs-CRP,IL-6 and Hcy were?218.39±31.77?mg/L,?4.11±0.35?mg/L,?218.37±58.73?pg/ml,?14.96±1.17?umol/L,all were lower than before treatment,and there was a statistical difference?P<0.05?.After1 year,the above indicators were further reduced,and the difference between the two groups was no statistical difference?P>0.05?.3 During the statin treatment,there was no significant change in ALT,AST,Cre,BUN,CK and FBG in the two groups?P>0.05?.At12 weeks,the AST of the every-other-day medication group was?23.56±7.05?U/L,and the AST of the daily medication group was?26.01±9.98?U/L,at 1 year,the Cre of the every-other-day medication group was?81.02±21.9?umol/L,the daily medication group was?86.67±21.62?umol/L,and there was statistical differences?P<0.05?.Number of people with impaired liver-kidney function in both groups was no statistical difference?P>0.05?.4 There were 13 cases?9.63%?of adverse reactions in every-other-day medication group,and 11 cases?10.47%?in another group,no statistical difference?P>0.05?.5 There was no significant difference in the incidence of MACE between the every-other-day medication group?7.41%?and the daily medication group?6.67%??P>0.05?.6 At the end of the trial,the every-other-day medication group spent RMB?1271.07±124.57?yuan,and another medication group was?2557.88±231.82?yuan,the cost of every-other-day group was less than daily medication group?P<0.01?.7 135?87.66%?patients in the every-other-day group completed the trial,and in daily medication group is 105?69.54%?.The medication compliance of the every-other-day medication group was better than daily medication group?P<00.1?.Conclusions1 Taking rosuvastatin every other day has the same effects on reducing the levels of blood lipid and inflammatory markers.2 Taking rosuvastatin every other day can improve compliance and save on treatment costs.Figure three;Table nine;Reference One hundred and forty one.